CU6 Financials: Results, Ratios & Statements | Clarity Pharmaceuticals

CU6

Clarity Pharmaceuticals

Pharmaceuticals, Biotechnology & Life Sciences

Clarity Pharmaceuticals is a clinical-stage company specializing in radiopharmaceuticals, focusing on theranostic products that combine therapy and imaging. Utilizing its proprietary SAR Technology, Clarity aims to improve cancer treatment outcomes with its Targeted Copper Theranostic platform. The company is positioned as a leader in next-generation radiopharmaceuticals, offering products that provide high accuracy and precision in cancer treatment.

Short position

short percentage8.94%

reported shorts33.3M

shares on issue373.081M

Clarity Pharmaceuticals (ASX:CU6) has 8.94% of its shares on issue reported as short positions as of 5 Oct 2026, or about 33,345,512 shares. Over the past 30 days that figure has risen 0.39 percentage points, and over 90 days it has risen 1.63 percentage points. Its highest recorded short interest was 10.24% in July 2025. CU6 is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

Latest result

Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency

Revenue: $0 (source: ASX (Markit))vs $0 (source: ASX (Markit)) (FY25); ASX (Markit), as at 29 Sep 2026
NPAT: −$107.2M (source: ASX (Markit))vs −$64.3M (FY25); ASX (Markit), as at 29 Sep 2026
EPS (diluted): −$0.29vs −$0.20 (FY25); Yahoo Finance, as at 29 Sep 2026

Rev YoY: n/aFY
EPS YoY: n/aFY

ASX (Markit)

Summary of Annual Report to shareholders, 30 Sep 2026

Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company that has not yet generated revenue or net profit, as it focuses on developing next-generation cancer treatments. The annual report highlights progress in Phase III trials (AMPLIFY and CLARIFY) and a strong cash balance of $178.3 million following a $203 million placement, but no dividend is declared. The company is preparing for potential FDA approval of its lead diagnostic agent, 64Cu-SAR-bisPSMA, with no specific financial guidance provided.

Automated summary of the filing; the filing itself is the record.

Key ratios

Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 9 Oct 2026

Gross margin: n/a
Operating margin: n/a
Net margin: n/a
FCF margin: n/a
ROE: n/a
ROA: n/a
FCF conversion: n/a
Net debt (excl. leases): n/a
Net debt / EBITDA: n/a
Current ratio: n/a
Interest cover: n/a
Cash dividends paid / net profit: n/a
Market cap: n/a (no share count we can vouch for)
P/E: n/a
P/B: n/a (no share count we can vouch for)

Ratios use the reporting currency (AUD); market cap is in AUD. Sources: Yahoo Finance, ASX (Markit) and Derived: trailing 12 months at year end, as at 29 Sep 2026.

Financial statements

Figures in AUD, the reporting currency; Yahoo Finance unless marked

CU6 income, newest period first, figures in AUD
Line item	FY26	FY25	FY24	FY23
Revenue	$0 (source: ASX (Markit))	$0 (source: ASX (Markit))	$0 (source: ASX (Markit))	$0 (source: ASX (Markit))
Operating income	−$118.9M (source: Derived: trailing 12 months at year end)	−$78.6M	−$56.3M	−$36.2M
EBITDA	−$118.6M (source: Derived: trailing 12 months at year end)	−$78.4M	−$56.2M	−$36.1M
EBIT	−$118.9M (source: Derived: trailing 12 months at year end)	−$78.6M	−$56.3M	−$36.2M
Pretax income	−$106.3M (source: Derived: trailing 12 months at year end)	−$63.9M	−$42.0M	−$24.5M
Tax	$860.6K (source: Derived: trailing 12 months at year end)	$416.5K	$295.2K	$103.2K
NPAT	−$107.2M (source: ASX (Markit))	−$64.3M	−$42.3M	−$24.6M
Net interest income	$8.0M (source: Derived: trailing 12 months at year end)	$4.8M	$2.8M	$1.9M
EPS basic	−$0.29	−$0.20	−$0.15	−$0.095
EPS diluted	−$0.29	−$0.20	−$0.15	−$0.095
Shares	n/a	321.5M	311.6M	132.5M

ASX (Markit)
Derived: trailing 12 months at year end

Financial reports

The company's own filings, newest first

Showing 10 of 61 reports